HC Wainwright Reaffirms Buy Rating for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on DARE. Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a research note on Saturday, August 16th. Maxim Group raised Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Thursday, September 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dare Bioscience presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Stock Performance

DARE opened at $1.75 on Tuesday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06. Dare Bioscience has a 1-year low of $1.61 and a 1-year high of $9.19. The company has a market cap of $24.93 million, a price-to-earnings ratio of -0.93 and a beta of 0.77. The company’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $2.30.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.01 million. On average, analysts expect that Dare Bioscience will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. AMH Equity Ltd lifted its holdings in shares of Dare Bioscience by 17.8% in the second quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after buying an additional 29,301 shares in the last quarter. Virtu Financial LLC bought a new stake in Dare Bioscience during the 3rd quarter worth approximately $37,000. Finally, Raymond James Financial Inc. lifted its stake in Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares in the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.